KORA (Kappa Opioid Receptor Agonists)

Finally, there is a potential
new path to pain relief.

Mu vs. Kappa.

KORAs target pain directly at peripheral
kappa-opioid receptors instead of mu-opioid receptors,
offering a promising new path in treating pain.

Central vs. Peripheral.

KORAs block pain at it source by
selectively activating kappa-opioid receptors located
on peripheral nerve terminals rather than the CNS.
Unlike mu-opioids, peripheral KORAs have a reduced ability
to cross the blood-brain barrier—minimizing abuse liability
and mu opioid-related side effects.

When mu-opioid related side effects
are a concern in a peri-operative setting.

Treatment of pain with classical mu opioids is associated with multiple side
effects, including sedation, respiratory depression, constipation, nausea, and
euphoria (which may lead to abuse potential).

When risk of abuse
is a concern in a clinical setting.

Peripherally restricted kappa opioid receptor agonists have shown
a possible lower abuse potential and side effect burden than mu opioid
receptor agonists making them promising targets for treating pain